



**Seracam® Abstracts Accepted at SNMMI in
Sentinel Lymph Node Biopsy and Clinical Nuclear Medicine Imaging Studies**

London, UK, 9 April 2025. Serac Imaging Systems Limited ("Serac Imaging Systems" or "the Company"), the medtech company developing 'Seracam®' a portable hybrid gamma-optical camera for medical imaging, announces that abstracts submitted by its clinical partners at the University of Malaya Medical Centre in Malaysia and The Ohio State University, USA, have been accepted for presentation at the prestigious Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting taking place from 21-24 June in New Orleans, USA.

One abstract titled **"Seracam™ hybrid optical-gamma camera for intraoperative imaging in breast cancer management: Preliminary results from a prospective trial"** presents findings comparing the use of Seracam® to a standard gamma probe in sentinel lymph node biopsy procedures in breast cancer patients. It is authored by Aik Hao Ng, Intan Noorliyana Md Musidek, Mohammad Nazri Md Shah and Mee Hoong See from the Faculty of Medicine at the University of Malaya, Chai Hong Yeong from the Faculty of Health and Medical Sciences, Taylor's University, Malaysia and Alan Perkins from the University of Nottingham, UK.

Another abstract titled **"Intraoperative, Bedside, Intradepartmental, Small Field of View Hybrid Optical-Gamma Camera Imaging System, Seracam™ with Specifications and First Clinical Use in the United States"** compares imaging with Seracam® with standard gamma camera imaging in patients attending for routine clinical nuclear medicine imaging. It is authored by Bonnie Williams and Emmanuel Appiah-Kubi from The Ohio State University, Luke Wonorski from Serac Imaging Systems and Alan Perkins from the University of Nottingham, UK.

- ENDS -

Seracam® is for investigational use only and has not been cleared or approved by the FDA or UK and European regulatory authorities.

For more information, please contact:

Mark Rosser, Chief Executive Officer

+44 (0)20 8948 0000

info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010 820

francettacarr@seraclifesciences.com

Notes to Editors

About Serac Imaging Systems and Seracam®

Serac Imaging Systems Ltd is a medtech company developing a portable hybrid gamma-optical camera for medical imaging. Our lead product is Seracam® which is in development to bring the benefits of high-resolution molecular imaging to a patient's bedside, instead of being confined for use in a hospital's nuclear medicine imaging department. A further unique feature of this technological approach is the overlay of a gamma image with an optical image of the same anatomical location under examination. Such portable and enhanced

imaging technology has the potential to help clinicians make better, more informed and more timely treatment decisions.

Seracam® is a UK and EU registered trademark. Serac Imaging Systems Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

For further details, please see www.seracimagingssystems.com

About molecular imaging

Molecular imaging is a type of medical imaging that provides unique insights into what is happening inside the body at the cellular and molecular level helping physicians to deliver personalised medicine by delivering the right treatment to the right patient at the right time. Unlike other medical imaging technologies such as x-rays, computed tomography (CT) and ultrasound (US) which provide structural images, molecular imaging allows physicians to see how cells, tissues and organs are functioning and to measure chemical and biological processes without having to resort to biopsy or surgery.

About SNMMI 2025: <https://snmmi.org/AM>